Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Correction Details.

Palau V, Riera M, Duran X, Valdivielso JM, Betriu A, Fernández E, Pascual J, Soler MJ.

Nephrol Dial Transplant. 2019 May 18. pii: gfz110. doi: 10.1093/ndt/gfz110. [Epub ahead of print] No abstract available.

PMID:
31106367
2.

An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.

Bermudez-Lopez M, Forne C, Amigo N, Bozic M, Arroyo D, Bretones T, Alonso N, Cambray S, Del Pino MD, Mauricio D, Gorriz JL, Fernandez E, Valdivielso JM.

Expert Opin Ther Targets. 2019 Jul;23(7):619-630. doi: 10.1080/14728222.2019.1620206. Epub 2019 May 23.

PMID:
31100024
3.

The rs1126616 Single Nucleotide Polymorphism of the Osteopontin Gene Is Independently Associated with Cardiovascular Events in a Chronic Kidney Disease Cohort.

Cambray S, Galimudi RK, Bozic M, Bermúdez-López M, Rodríguez I, Valdivielso JM.

J Clin Med. 2019 Apr 29;8(5). pii: E592. doi: 10.3390/jcm8050592.

4.

Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort.

Valls J, Cambray S, Pérez-Guallar C, Bozic M, Bermúdez-López M, Fernández E, Betriu À, Rodríguez I, Valdivielso JM.

Front Genet. 2019 Feb 26;10:118. doi: 10.3389/fgene.2019.00118. eCollection 2019.

5.

Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage.

Rayego-Mateos S, Rodrigues-Diez R, Morgado-Pascual JL, Valentijn F, Valdivielso JM, Goldschmeding R, Ruiz-Ortega M.

Mediators Inflamm. 2018 Dec 23;2018:8739473. doi: 10.1155/2018/8739473. eCollection 2018. Review.

6.

Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology.

Morgado-Pascual JL, Marchant V, Rodrigues-Diez R, Dolade N, Suarez-Alvarez B, Kerr B, Valdivielso JM, Ruiz-Ortega M, Rayego-Mateos S.

Mediators Inflamm. 2018 Dec 13;2018:2931049. doi: 10.1155/2018/2931049. eCollection 2018. Review.

7.

Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium.

Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M; CKD Prognosis Consortium (CKD-PC).

BMJ. 2019 Jan 10;364:k5301. doi: 10.1136/bmj.k5301.

8.

Peritoneal Dialysis Is an Independent Factor Associated to Lower Intima Media Thickness in Dialysis Patients Free From Previous Cardiovascular Disease.

Borràs M, Cambray S, Crespo-Masip M, Pérez-Fontán M, Bozic M, Bermudez-López M, Fernández E, Betriu À, Valdivielso JM.

Front Physiol. 2018 Dec 4;9:1743. doi: 10.3389/fphys.2018.01743. eCollection 2018.

9.

Author Correction: Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0099-y.

PMID:
30538326
10.

Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9. Review. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30361677
11.

Sex hormones and their influence on chronic kidney disease.

Valdivielso JM, Jacobs-Cachá C, Soler MJ.

Curr Opin Nephrol Hypertens. 2019 Jan;28(1):1-9. doi: 10.1097/MNH.0000000000000463. Review.

PMID:
30320621
12.

Inflammation in Diabetic Kidney Disease.

Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF.

Nephron. 2018 Oct 1:1-5. doi: 10.1159/000493278. [Epub ahead of print] Review.

13.

Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.

Arcidiacono MV, Rimondi E, Maietti E, Melloni E, Tisato V, Gallo S, Valdivielso JM, Fernández E, Betriu À, Voltan R, Zauli G, Volpato S, Secchiero P.

PLoS One. 2018 Sep 11;13(9):e0203716. doi: 10.1371/journal.pone.0203716. eCollection 2018.

14.

Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients.

Palau V, Riera M, Duran X, Valdivielso JM, Betriu A, Fernández E, Pascual J, Soler MJ.

Nephrol Dial Transplant. 2018 Aug 8. doi: 10.1093/ndt/gfy240. [Epub ahead of print]

PMID:
30102333
15.

Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes.

Palanca A, Castelblanco E, Perpiñán H, Betriu À, Soldevila B, Valdivielso JM, Bermúdez M, Duran X, Fernández E, Puig-Domingo M, Groop PH, Alonso N, Mauricio D.

Atherosclerosis. 2018 Sep;276:50-57. doi: 10.1016/j.atherosclerosis.2018.07.018. Epub 2018 Jul 19.

PMID:
30032025
16.

Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease.

Valdivielso JM, Bozic M, Galimudi RK, Bermudez-López M, Navarro-González JF, Fernández E, Betriu À; NEFRONA investigators.

Nephrol Dial Transplant. 2018 Jul 13. doi: 10.1093/ndt/gfy207. [Epub ahead of print]

PMID:
30010839
17.

Correction: The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease.

Borràs Sans M, Pérez-Fontán M, Martinez-Alonso M, Bajo A, Betriu À, Valdivielso JM, Fernández E; NEFRONA INVESTIGATORS.

PLoS One. 2018 Jun 28;13(6):e0200226. doi: 10.1371/journal.pone.0200226. eCollection 2018.

18.

Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project.

Sánchez E, Lecube A, Betriu À, Hernández C, López-Cano C, Gutiérrez-Carrasquilla L, Kerkeni M, Yeramian A, Purroy F, Pamplona R, Farràs C, Fernández E, Barbé F, Simó R; ILERVAS project, Hernández M, Rius F, Polanco D, de la Torre MS, Torres G, Godoy P, Portero-Otin M, Jové M, Colàs-Compàs L, Benabdelhak I, Miquel E, Ortega M, Valdivielso JM, Bermúdez M, Martínez-Alonso M.

Diabetes Metab. 2018 Apr 13. pii: S1262-3636(18)30079-X. doi: 10.1016/j.diabet.2018.04.002. [Epub ahead of print] No abstract available.

PMID:
29706471
19.

Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors.

Montserrat-Capdevila J, Seminario MA, Godoy P, Marsal JR, Ortega M, Pujol J, Castañ MT, Alsedà M, Betriu À, Lecube A, Portero M, Purroy F, Valdivielso JM, Barbé F.

Med Clin (Barc). 2018 Nov 21;151(10):383-389. doi: 10.1016/j.medcli.2017.12.018. Epub 2018 Mar 7. English, Spanish.

PMID:
29525115
20.

Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.

Bozic M, Betriu A, Bermudez-Lopez M, Ortiz A, Fernandez E, Valdivielso JM; NEFRONA investigators.

Clin J Am Soc Nephrol. 2018 Apr 6;13(4):577-584. doi: 10.2215/CJN.07980717. Epub 2018 Mar 8.

21.

Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.

Bozic M, Méndez-Barbero N, Gutiérrez-Muñoz C, Betriu A, Egido J, Fernández E, Martín-Ventura JL, Valdivielso JM, Blanco-Colio LM; investigators from the NEFRONA study.

Atherosclerosis. 2018 Mar;270:13-20. doi: 10.1016/j.atherosclerosis.2018.01.011. Epub 2018 Feb 4.

PMID:
29407881
22.

Beyond the traditional lipid parameters in chronic kidney disease.

Bermúdez-López M, Betriu À, Valdivielso JM, Bretones Del Pino T, Arroyo D, Fernández E.

Nefrologia. 2018 Mar - Apr;38(2):109-113. doi: 10.1016/j.nefro.2017.09.008. Epub 2017 Nov 11. English, Spanish. No abstract available.

23.

The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease.

Borràs Sans M, Pérez-Fontán M, Martinez-Alonso M, Bajo A, Betriu À, Valdivielso JM, Fernández E; NEFRONA INVESTIGATORS.

PLoS One. 2017 Nov 2;12(11):e0186921. doi: 10.1371/journal.pone.0186921. eCollection 2017. Erratum in: PLoS One. 2018 Jun 28;13(6):e0200226.

24.

Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound.

Valdivielso JM, Betriu A, Martinez-Alonso M, Arroyo D, Bermudez-Lopez M, Fernandez E; NEFRONA investigators.

PLoS One. 2017 Oct 18;12(10):e0186665. doi: 10.1371/journal.pone.0186665. eCollection 2017.

25.

The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway.

Khan AUH, Allende-Vega N, Gitenay D, Gerbal-Chaloin S, Gondeau C, Vo DN, Belkahla S, Orecchioni S, Talarico G, Bertolini F, Bozic M, Valdivielso JM, Bejjani F, Jariel I, Lopez-Mejia IC, Fajas L, Lecellier CH, Hernandez J, Daujat M, Villalba M.

Sci Rep. 2017 Sep 6;7(1):10654. doi: 10.1038/s41598-017-10339-5.

26.

New perspectives on CKD-induced dyslipidemia.

Bermúdez-López M, Arroyo D, Betriu À, Masana L, Fernández E, Valdivielso JM.

Expert Opin Ther Targets. 2017 Oct;21(10):967-976. doi: 10.1080/14728222.2017.1369961. Epub 2017 Aug 28. Review.

PMID:
28829206
27.

Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.

Fernández-Laso V, Méndez-Barbero N, Valdivielso JM, Betriu A, Fernández E, Egido J, Martín-Ventura JL, Blanco-Colio LM.

Atherosclerosis. 2017 May;260:130-137. doi: 10.1016/j.atherosclerosis.2017.03.043. Epub 2017 Mar 31.

PMID:
28390291
28.

Low Serum Levels of Vitamin D are Associated with Progression of Subclinical Atherosclerotic Vascular Disease in Peritoneal Dialysis Patients: A Prospective, Multicenter Study.

Pérez Fontán M, Borràs Sans M, Bajo Rubio MA, Rodriguez-Carmona A, Betriu A, Valdivielso JM, Fernández E; NEFRONA Study investigators.

Nephron. 2017;136(2):111-120. doi: 10.1159/000458418. Epub 2017 Feb 25.

PMID:
28237990
29.

High Levels of Hemoglobin Promote Carotid Adventitial Vasa Vasorum Neoangiogenesis in Chronic Kidney Disease.

Arcidiacono MV, Martinez-Alonso M, Belart M, Vilar A, Martín M, Craver L, Betriu À, Mauricio D, Valdivielso JM, Fernández E, Borràs M.

Mediators Inflamm. 2017;2017:3795142. doi: 10.1155/2017/3795142. Epub 2017 Jan 4.

30.

Effects of the Administration of 25(OH) Vitamin D3 in an Experimental Model of Chronic Kidney Disease in Animals Null for 1-Alpha-Hydroxylase.

Torremadé N, Bozic M, Goltzman D, Fernandez E, Valdivielso JM.

PLoS One. 2017 Jan 20;12(1):e0170654. doi: 10.1371/journal.pone.0170654. eCollection 2017.

31.

Vascular Calcification Induced by Chronic Kidney Disease Is Mediated by an Increase of 1α-Hydroxylase Expression in Vascular Smooth Muscle Cells.

Torremadé N, Bozic M, Panizo S, Barrio-Vazquez S, Fernandez-Martín JL, Encinas M, Goltzman D, Arcidiacono MV, Fernandez E, Valdivielso JM.

J Bone Miner Res. 2016 Oct;31(10):1865-1876. doi: 10.1002/jbmr.2852. Epub 2016 May 4.

32.

Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease.

Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, Clotet S, Mojal S, Fernández E, Soler MJ; investigators from the NEFRONA study.

Atherosclerosis. 2016 Oct;253:135-143. doi: 10.1016/j.atherosclerosis.2016.08.032. Epub 2016 Aug 24.

PMID:
27615597
33.

Mineral metabolism factors predict accelerated progression of common carotid intima-media thickness in chronic kidney disease: the NEFRONA study.

Abajo M, Betriu À, Arroyo D, Gracia M, Del Pino MD, Martínez I, Valdivielso JM, Fernández E; Investigators of the NEFRONA study.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1882-1891. doi: 10.1093/ndt/gfw306.

PMID:
27566835
34.

Quality Assurance of Samples and Processes in the Spanish Renal Research Network (REDinREN) Biobank.

Calleros-Basilio L, Cortés MA, García-Jerez A, Luengo-Rodríguez A, Orozco-Agudo A, Valdivielso JM, Rodríguez-Puyol D, Rodríguez-Puyol M.

Biopreserv Biobank. 2016 Dec;14(6):499-510. Epub 2016 Aug 19.

PMID:
27541936
35.

Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.

Bozic M, Guzmán C, Benet M, Sánchez-Campos S, García-Monzón C, Gari E, Gatius S, Valdivielso JM, Jover R.

J Hepatol. 2016 Oct;65(4):748-757. doi: 10.1016/j.jhep.2016.05.031. Epub 2016 May 28.

PMID:
27245430
36.

Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study.

Arroyo D, Betriu A, Valls J, Gorriz JL, Pallares V, Abajo M, Gracia M, Valdivielso JM, Fernandez E; Investigators from the NEFRONA study.

Nephrol Dial Transplant. 2017 Mar 1;32(3):513-520. doi: 10.1093/ndt/gfw039.

PMID:
27190385
37.

Randomised intervention study to assess the prevalence of subclinical vascular disease and hidden kidney disease and its impact on morbidity and mortality: The ILERVAS project.

Betriu À, Farràs C, Abajo M, Martinez-Alonso M, Arroyo D, Barbé F, Buti M, Lecube A, Portero M, Purroy F, Torres G, Valdivielso JM, Fernández E.

Nefrologia. 2016 Jul-Aug;36(4):389-96. doi: 10.1016/j.nefro.2016.02.008. Epub 2016 Apr 1. English, Spanish.

38.

Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.

Fernández-Laso V, Sastre C, Valdivielso JM, Betriu A, Fernández E, Egido J, Martín-Ventura JL, Blanco-Colio LM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):413-22. doi: 10.2215/CJN.07900715. Epub 2016 Jan 4.

39.

Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.

Gracia M, Betriu À, Martínez-Alonso M, Arroyo D, Abajo M, Fernández E, Valdivielso JM; NEFRONA Investigators.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):287-96. doi: 10.2215/CJN.01240215. Epub 2015 Dec 14.

40.

Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development.

Bozic M, Álvarez Á, de Pablo C, Sanchez-Niño MD, Ortiz A, Dolcet X, Encinas M, Fernandez E, Valdivielso JM.

PLoS One. 2015 Aug 31;10(8):e0136863. doi: 10.1371/journal.pone.0136863. eCollection 2015.

41.

Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.

Barrios C, Pascual J, Otero S, Soler MJ, Rodríguez E, Collado S, Faura A, Mojal S, Navarro-González JF, Betriu A, Fernandez E, Valdivielso JM; investigators of the NEFRONA study.

Atherosclerosis. 2015 Sep;242(1):37-44. doi: 10.1016/j.atherosclerosis.2015.06.048. Epub 2015 Jun 30.

PMID:
26177272
42.

Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells.

Morgado-Pascual JL, Rayego-Mateos S, Valdivielso JM, Ortiz A, Egido J, Ruiz-Ortega M.

Biomed Res Int. 2015;2015:783538. doi: 10.1155/2015/783538. Epub 2015 May 6.

43.

Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease.

Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, Mojal S, Fernández E, Soler MJ; NEFRONA study.

Nephrol Dial Transplant. 2015 Jul;30(7):1176-85. doi: 10.1093/ndt/gfv025. Epub 2015 Mar 26.

PMID:
25813276
44.

Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference.

Martín M, Valls J, Betriu A, Fernández E, Valdivielso JM.

Atherosclerosis. 2015 Jul;241(1):264-70. doi: 10.1016/j.atherosclerosis.2015.02.048. Epub 2015 Feb 28.

PMID:
25748053
45.

Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.

Fernández-Laso V, Sastre C, Valdivielso JM, Fernández E, Martín-Ventura JL, Egido J, Blanco-Colio LM.

Atherosclerosis. 2015 Apr;239(2):358-63. doi: 10.1016/j.atherosclerosis.2015.01.040. Epub 2015 Feb 7.

PMID:
25681674
46.

The potential of targeting NMDA receptors outside the CNS.

Bozic M, Valdivielso JM.

Expert Opin Ther Targets. 2015 Mar;19(3):399-413. doi: 10.1517/14728222.2014.983900. Epub 2014 Dec 13. Review.

PMID:
25495517
47.

The active form of vitamin D, calcitriol, induces a complex dual upregulation of endothelin and nitric oxide in cultured endothelial cells.

Martínez-Miguel P, Valdivielso JM, Medrano-Andrés D, Román-García P, Cano-Peñalver JL, Rodríguez-Puyol M, Rodríguez-Puyol D, López-Ongil S.

Am J Physiol Endocrinol Metab. 2014 Dec 15;307(12):E1085-96. doi: 10.1152/ajpendo.00156.2014. Epub 2014 Oct 21.

48.

Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study.

Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fernández E; investigators from the NEFRONA study.

BMC Nephrol. 2014 Oct 18;15:168. doi: 10.1186/1471-2369-15-168.

49.

High phosphate diet increases arterial blood pressure via a parathyroid hormone mediated increase of renin.

Bozic M, Panizo S, Sevilla MA, Riera M, Soler MJ, Pascual J, Lopez I, Freixenet M, Fernandez E, Valdivielso JM.

J Hypertens. 2014 Sep;32(9):1822-32. doi: 10.1097/HJH.0000000000000261.

PMID:
24979301
50.

Lack of vitamin D receptor causes stress-induced premature senescence in vascular smooth muscle cells through enhanced local angiotensin-II signals.

Valcheva P, Cardus A, Panizo S, Parisi E, Bozic M, Lopez Novoa JM, Dusso A, Fernández E, Valdivielso JM.

Atherosclerosis. 2014 Aug;235(2):247-55. doi: 10.1016/j.atherosclerosis.2014.05.911. Epub 2014 May 13.

PMID:
24880896

Supplemental Content

Loading ...
Support Center